Joe Salvani - Significance of CBLI Radiation Antidote to Nuclear Crisis in Fukushima, Japan

Cleveland BioLabs is a biotechnology company focused on the development of innovative drugs to treat cancer and protect healthy tissues from radiation poisoning caused by a nuclear explosion or cancer treatment.

Japan's nuclear crisis has put Cleveland BioLabs lead drug, known as CBLB502, in the spotlight as the risks of a catastrophe are grave and growing with the effects of a nuclear meltdown. Although the company's radiation treatment is still in development, it has been fast-tracked by U.S. FDA and is expected to be approved in the U.S. in late 2012 or early 2013.

Joe Salvani, an authority in biotechnology who began his career on Wall Street as Senior Vice President and Chemical Industry Analyst at Goldman Sachs, discusses the significance of Cleveland BioLabs drug as a radiation antidote and the near-term outlook for the company.

Category:

Science & Technology

Tags:

• radiation
• Nuclear
• Fukushima
• Japan
• biotech